Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

By afschroeder • April 28, 2026

Cho BC, Nishio M, Ahn MJ, García-Campelo R, Ponce S, Baik C, Salgia R, Kim SW, Lee JS, Yoshida T, Yu HA, Goldberg SB, Johannes de Langen A, Le X, Piotrowska Z, Riess JW, Tanaka K, Ambrose H, Cosaert J, Fraenkel PG, Tang KH, Lehman JM, Smith P, Goldman JW. Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD. JTO Clin Res Rep. 2026 Mar 23;7(4):100937. doi: 10.1016/j.jtocrr.2025.100937. PMID: 42039685; PMCID: PMC13107052.

Tags: chemotherapy, durvalumab, Epidermal growth factor receptor mutated, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications

CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer

Alcantar JM, Chuang FL, Kim DD. CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer. Cureus. 2026 Mar 25;18(3):e105839. doi: 10.7759/cureus.105839. PMID: 42037944; PMCID: PMC13108622.

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp[...]

Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach

Idossa D, Hennessy MA, LeVee A, Nanda R, McArthur H, Leon-Ferre RA. Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. Am[...]